Myocardial injury and disease often result in heart failure, a major cause of death worldwide. To achieve myocardial regeneration and foster development of efficient therapeutics for cardiac injury, it is essential to uncover molecular mechanisms that will promote myocardial regeneration. In this review, we examine the latest progress made in elucidation of the roles of small non-coding RNAs called microRNAs (miRs) in myocardial regeneration.
INTRODUCTION
Compromised myocardial function with heart failure is a worldwide major cause of morbidity and mortality [1, 2] . Heart transplantation remains the most effective treatment strategy for end-stage heart failure, but can barely meet the increasing global demand because of the scarcity of donor hearts [3] . Unlike amphibians and fish [4] [5] [6] [7] [8] , mammalian cardiomyocytes have limited renewal capacity, compromising the ability of mammalian hearts to efficiently repair after injury [9] [10] [11] [12] [13] . Because of these limitations, researchers are constantly pursuing novel approaches toward therapies that could ameliorate heart failure. Currently, there is no available approach to reverse the loss of functional myocardium [14] . Efficacious regenerative therapeutics to reverse the progression of heart failure has become an urgent and critical goal of modern cardiovascular research.
Considerable effort has been extended to develop therapies based on transplantation of stem cells or different types of progenitor cells to help a failing heart repopulate with newly made cardiomyocytes [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . An alternative and promising cell-free tactic is to use small molecules or paracrine factors to stimulate cardiomyocyte proliferation or differentiation of resident cardiac progenitor cells [25] [26] [27] [28] [29] [30] [31] . Recent progress made in reprogramming and transdifferentiation of noncardiomyocytes also shows great promise to advance cardiac regeneration [32] [33] [34] [35] [36] [37] [38] [39] 40 & , [41] [42] [43] [44] [45] . Moreover, additional investigations aim to dissect signaling pathways regulating endogenous cardiomyocyte regenerative capacity [46] [47] [48] [49] [50] [51] . MicroRNAs (miRs) are small endogenous noncoding single-stranded RNAs that function in biologic processes, primarily via post-transcriptional gene silencing in diverse organisms [52, 53] . miRs generally repress target gene expression by promoting mRNA degradation and/or inhibiting translation. Genes targeted by a miR have conserved Watson-Crick base pairing to the miR 'seed' site, which is centered at the 5 0 end of the miR [54, 55] . The essential roles of miRs have been shown in regeneration of different tissues and organs. For example, miR-133 promotes appendage regeneration in zebra fish [56] , whereas miR-206 promotes the regeneration of neuromuscular synapses [57] and skeletal muscle [58] in mice. Although the mechanisms remain largely unknown, miRs have been shown to have critical functions in cardiac regeneration. For example, previous studies showed that a combination of miRs (miR-1, miR-133, miR-208, and miR-499) has the capability of reprogramming cardiac fibroblasts into cardiomyocytes [40 & ]. Previous reviews have summarized the progress made in studying reprogramming and regenerating cardiac tissue, including critical miRs involved in cardiac development and homeostasis [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] . Here, we summarize the most recent investigations into the function of miRs in myocardial regeneration.
microRNAs PLAY AN ESSENTIAL ROLE IN MYOCARDIAL REGENERATION
has-microRNA-590 and has-microRNA-199a
To identify miRs that function in cardiomyocyte proliferation, a recent study cultured neonatal rat ventricular cardiomyocytes and transfected them with a library of 875 human miR mimics in a high-throughput screening approach [70 && ]. Based on that screening, 204 miRs significantly increased neonatal rat cardiomyocyte proliferation and 40 miRs from the original 204 miRs also increased cytokinesis and karyokinesis in neonatal mouse cardiomyocytes [70 && ]. Among the 40 miRs, hsamiR-590-3p, hsa-miR-199a-3p, hsa-miR-33b, and hsamiR-1825 can significantly increase the proliferation of 7-day postnatal cardiomyocyte, and, even more remarkably, hsa-miR-590-3p and hsa-miR-199a-3p can significantly increase 2-month adult cardiomyocyte proliferation [70 && ]. Hsa-miR-33b has been previously shown to have a role in regulating cell proliferation and fatty acid metabolism [71] [72] [73] , whereas hsa-miR-1825 function was previously unclear. This study chose to focus on hsa-miR-590-3p and hsa-miR-199a-3p for further miR target studies, given that these two miRs were the most effective at promoting proliferation in rat and mouse cardiomyocytes respectively.
The miR target genes controlling cardiomyocyte proliferation were globally identified using a combined RNA deep-sequencing and small interfering RNA screening approach [70 && ]. The authors were able to identify three targets, Homer protein homolog 1 (Homer1), Homeodomain-only protein x (Hopx), and Chloride intracellular channel protein 5 (Clic5), which are miR regulated and also modulate cardiomyocyte cell proliferation. Further luciferase reporter assays indicated Homer1 and Hopx are targeted by both hsa-miR-590-3p and hsa-miR-199a-3p, whereas Clic5 is only targeted by hsa-miR-590-3p. Homer1 previously has been shown to interact with ryanodine receptor (RyR) to control intracellular calcium signaling and with phosphatidylinositide 3-kinase to prevent cell apoptosis [74] [75] [76] [77] . Hopx, an atypical homeodomain-protein, regulates proliferation and differentiation of different cell types, including cardiomyocyte proliferation by modulating Gata4 acetylation and serum response factor-dependent gene expression [78] [79] [80] [81] [82] . Hopx is expressed in both embryonic and postnatal cardiomyocytes and its transcript level was found to be significantly reduced in both human and mouse hearts with heart failure [78, 79, 83] .
Consistently with the in-vitro data, in-vivo analysis using synthetic miRs indicated that overexpression of hsa-miR-590-3p and hsa-miR-199a-3p increased cardiomyocyte proliferation in neonatal mice [70 && ]. After myocardial infarction (MI), mouse hearts transduced with AAV9-miR-590-3p and AAV9-miR-199a-3p had improved cardiac function and reduced fibrotic scar size compared with controls [70 && ]. Together, this study suggested that hsa-miR-590-3p and hsa-miR-199a-3p can stimulate cardiac regeneration by promoting mature KEY POINTS miRs have the capabilities to regulate cardiac reprogramming and regeneration. miRs function in cardiac repair by regulating proliferation, apoptosis, metabolism, angiogenesis, and senescence. miRs have multiple targets, making the molecular mechanisms more complicated such that the same miR may function differently after different types of cardiac injuries.
Manipulation of miR levels can be achieved by antagomirs/LNA antimiR and miR mimics/AAV9-miR, making miR-based therapeutics feasible.
In addition to the work investigating miR-199a discussed above, other studies indicated that miR199a repressed hypoxia-inducible factor-1 a and Sirtuin 1 [84] , as well as the ubiquitin-proteasome system [85] in mouse hearts. Meanwhile, miR-199a was modulated by high glucose and hypoxia in heart failure patients [86] and miR-199a-214 cluster was downregulated in explanted cardiac tissue from patients with dilated cardiomyopathy [87] .
A recent study indicated that miR-199a-214 cluster is involved in heart failure by facilitating a maladaptive metabolic shift to increased glucose metabolism rather than fatty acid utilization normally found in healthy myocardium [88 & ]. Using a cardiac disease mouse model with transverse aortic constriction (TAC) pressure overload, the authors found that mice treated with antagomirs of miR-199a and miR-214 had improved cardiac function as well as normal arrangement of cardiomyocytes, significantly reduced cardiac fibrosis and hypertrophy, whereas vehicle-treated control hearts had impaired cardiac function and displayed cardiomyocyte disarray, interstitial fibrosis, and hypertrophied myofibers [88 & ]. The mechanistic studies indicated that both miR-199a and miR-214 directly repressed peroxisome proliferator-activated receptor delta (PPARd), a critical regulator of mitochondrial fatty acid metabolism in heart, but did not alter expression of genes involved in glucose metabolism [88 & ].
microRNA-17-92 cluster
The miR-17-92 cluster encodes six polycistronic miRs (miR-17, miR-18a, miR-19a, miR-20a, miR-19b, and miR-92a), of which some miRs have the same seed site. miR-17-92 germline loss-of-function resulted in abnormal myocardial differentiation from second heart field cardiac progenitors, by repressing the cardiac progenitor gene Isl1 during embryonic cardiac development [89] . miR-17-92 also represses T-box genes during cardiac and craniofacial morphogenesis [89, 90] . miR-92a inhibits endothelial cell migration and angiogenesis in adult mice, whereas inhibition of miR-92a improves heart function and angiogenesis after MI or vascular injury [91, 92] . A recent study reported that miR-17-92, particularly miR-19 as a key component, can induce proliferation of cardiomyocytes and help protect the heart from ischemic injury caused by MI [93 & ]. Compared with controls, proliferation of cardiomyocytes was decreased in miR-17-92 loss-of-function hearts and increased in miR-17-92 gain-of-function hearts. Importantly, after MI, miR-17-92 gain-of-function hearts had improved cardiac function, reduced scar size, and more proliferating cardiomyocytes at the border zone when compared with controls, suggesting an essential role in cardiac regeneration. In-vitro analysis suggests that miR-17-92 induces cardiomyocyte proliferation through direct repression of phosphatase and tensin homolog (PTEN) by miR-19, a tumor suppressor previously shown to be a miR-17-92 target in tumorgenesis [94] .
microRNA-34a
Aging is a critical risk factor for heart diseases, and old patients with cardiac injury usually have worse outcome than young patients [95] . Compared with young mice, the aged mouse heart has increased cardiomyocyte apoptosis, fibrosis, and hypertrophy, with decreased telomere length [96 & ]. The expression levels of miR-34a, which previously had been shown as a regulator in apoptosis and senescence [97] [98] [99] [100] [101] , were higher in older human and mouse hearts compared with young hearts [96 & ]. In-vitro data indicated this age-induced miR promoted H 2 O 2 -induced apoptosis in rat neonatal cardiomyocytes [96 & ]. In-vivo assays using miR-34a antagomir treatment further indicated that miR-34a induced cell death [96 & ]. Moreover, miR-34a-knockout mice had less cell death and hypertrophy, as well as better cardiac contractile function compared with wildtype mice [96 & ]. Notably, after acute MI, miR-34a expression was significantly increased at the border zone and treatment with miR-34a antagomirs or locked nucleic acid (LNA)-based antimiRs significantly improved cardiac function [96 & ]. A key target of miR-34a identified in this study is Pnuts (also known as Ppp1r10), which is a gene previously reported in modulating apoptosis, telomere shortening, and DNA repair [102] .
microRNA-15 family
Mouse neonatal hearts can regenerate after injury, but this ability is gradually lost by postnatal day (P) 7 [49] . The expression levels of miR-15, miR-30, and let-7 families were increased in P10 compared with P1 mouse heart, suggesting a functional role in the transition to non-regenerative myocardium [103] . Transfection data on rat cardiomyocytes indicated that miR-518 and miR-302 family promoted cardiomyocyte proliferation, whereas Let-7 and miR-15 family inhibited proliferation [70 && ]. The miR-15 family, consisting of six closely related miRs (miR-15a, miR-15b, miR-16-1, miR-16-2, miR-195, and miR-497), was upregulated in different heart diseases [104] . Cardiac-specific overexpression of miR-195 [MYH7-miR-195 transgenic (TG)] resulted in premature cell cycle arrest at G2 phase, leading to reduced heart size and congenital heart abnormalities such as ventricular hypoplasia and ventricular septal defects [103] . Mouse hearts treated with LNA antimiR15 to inhibit miR-15 had reduced infarct size and enhanced cardiac function after ischemia-reperfusion surgery [105] . Wild-type P1 mouse hearts regenerate after MI and the newly formed cardiomyocytes are derived mainly from preexisting cardiomyocytes [106 & ]. However, after MI, MYH7-miR-195 TG hearts failed to regenerate and had significantly impaired cardiac function compared with wild-type hearts, perhaps due to induction of inflammatory genes and repression of mitochondrial and cell cycle genes [106 & ]. Conversely, LNA antimiR15 treatment increased proliferation of cardiomyocytes and improved left ventricular systolic function after adult MI [106 & ]. It has been reported that miR-195 contributed to the repression of a number of cell cycle genes, including checkpoint kinase 1 (Chek1), cyclin-dependent kinase 1 (Cdk1), baculoviral IAP repeat-containing 5 (Birc5), nucleolar and spindleassociated protein 1 (Nusap1), and sperm-associated antigen 5 (Spag5) [103] . Among these cell cycle genes, Chek1 has the miR-195 seed site conserved between mice and humans and was directly targeted by miR-195 based on the luciferase reporter analysis [103] . Chek1 is a cell cycle gene that coordinates mitotic progression with spindle checkpoints [103] . Recently, a hepatocellular carcinoma study found that miR-195 suppressed cancer cell proliferation and led to reduced tumor size through directly targeting nuclear factor-kB signaling-related genes IKKa and TAB3 [107] [108] [109] .
CONCLUSION
Important recent progress has been made in the field of cardiac regeneration research. The success of cellbased therapies for heart repair, though measurable, has been modest to date likely because the infused cells fail to efficiently integrate into the heart. Moreover, reprogramming and transdifferentiation of non-cardiomyocytes are limited by poor efficiency and other technical challenges [15-20,32-39, 40 & ,64]. Thus, new innovative strategies are needed to enhance cardiac regeneration, and one of the alternative compelling strategies is to trigger the endogenous cardiomyocyte regenerative capacity. Exciting new findings, revealed in the last few years, indicate that resident cardiomyocytes can be induced to re-enter the cell cycle and undergo cytokinesis. More work is needed to investigate the underlying molecular mechanisms for induced cardiomyocyte cell cycle re-entry. The studies summarized in this review indicate that miR-based therapeutics, using miR antagonists or mimics, has strong potential to be used to promote cardiomyocyte cell cycle re-entry and improve cardiac function after cardiac injury.
A majority of myocardial regeneration-related miRs, or regenerative miRs, play essential roles in cell proliferation (Fig. 1, Table 1 ), not only in cardiomyocytes, but also in many other cell types. Moreover, their functions in proliferation are conserved between species from mouse to human. For example, miR-17-92 cluster was the first described oncogenic miR [110, 111] , whereas miR-15a and miR-16 are the first identified tumor suppressor miRs [112] . Notably, regenerative miRs could share the same target genes during myocardial regeneration as they do in other contexts. For example, individual miR-15 family members, which have the same seed site, have characterized targets in contexts other than heart regeneration [107] [108] [109] . These characteristics would enable cardiac researchers to investigate candidate target genes for the miR-15 family in the context of cardiac regeneration.
Other regenerative miRs have different mechanisms of modulating cardiac function after injury (Fig. 1, Table 1) . As an example, miR-34a mainly regulated apoptosis and senescence during cardiac repair [96 & ]. Notably, miRs within the same cluster may modulate cardiac function via independent mechanisms. For example, within the miR-17-92 cluster, miR-19 regulates cardiomyocyte proliferation, whereas miR-92a inhibits angiogenesis [91, 92] . Moreover, the same miR could play different roles after different types of cardiac injury. Taking miR-199a as an example, in mice with TAC pressure overload, miR-199a inhibition with antagomir-199a improved cardiac contractility [88 & ]. In contrast, overexpression of miR-199a using AAV9-199a induced cardiac regeneration in mice after MI [70 && ]. A potential explanation, worthy of further investigation, for those observations is that miRs have multiple targets and repress different targets in the context of different injury types.
Although progress is promising, current miR studies on myocardial regeneration are limited to some extent because of the lack of cardiomyocyte specificity of in-vivo antimiR administration protocols; therefore, new technologies or further studies are still needed to address these limitations. For example, LNA antimiR15 treatment increased cardiomyocyte proliferation after MI, but also robustly induced proliferation of the non-cardiomyocyte compartment [106 & ]. It is unknown whether this non-cardiomyocyte effect is necessary for cardiac repair or influences therapeutic efficacy. Moreover, treatment using antimiR chemistries could efficiently improve cardiac function in mouse and in some cases even in pig, but whether these approaches could sufficiently repair injured human hearts remains to be demonstrated. Studies in nonhuman primates and eventually human patients are needed. and funding from the Vivian L. Smith Foundation (to J.F.M.).
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